Cai Jing Wang·2025-08-27 04:53Group 1 - The company reported a net cash flow from operating activities of 2.134 billion yuan, representing a year-on-year increase of 11.90% [2] - In the first half of 2025, the company's revenue from the pharmaceutical sector was 13.901 billion yuan, accounting for 71.24% of total revenue, while in the same period of 2024, it was 14.677 billion yuan, accounting for 71.72% [2] - The company has signed agreements for the disposal of non-strategic and non-core assets totaling over 2 billion yuan since the beginning of 2025, aiming to optimize asset structure and accelerate cash flow [3] Group 2 - The company invested a total of 2.584 billion yuan in research and development in the first half of 2025, with R&D expenses amounting to 1.717 billion yuan [3] - Revenue from medical devices and diagnostics was 1.955 billion yuan, representing 10.02% of total revenue in the first half of 2025, compared to 2.069 billion yuan and 10.11% in the same period of 2024 [2] - The company is enhancing its innovation and R&D system through various collaboration models, including independent research, cooperative development, licensing, and industrial investment [3]